Neurocrine Biosciences Inc (NBIX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $16.94B
Last updated: Nov 17, 2026 at 11:05 AM ET
Neurocrine Biosciences Inc (NBIX) Financials: Revenue, Profit and Cash Flow
Neurocrine Biosciences reported revenue of $2.86B for the fiscal year ended Dec 31, 2025, up 21.4% from the year before. That year, net income was $478.60M with a net margin of 16.7%, operating cash flow was $782.70M and free cash flow was $748.70M. The quarter ended Sep 30, 2026 had revenue of $1.12B and net income of $206.50M.
Revenue and Margins
The operating margin was 21.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $15.00M, a compound annual rate of 79.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.86B | +21.4% | 98.2% | 21.6% | 16.7% |
| Dec 2024 | $2.36B | +24.8% | 98.6% | 24.2% | 14.5% |
| Dec 2023 | $1.89B | +26.8% | 97.9% | 13.3% | 13.2% |
| Dec 2022 | $1.49B | +31.3% | 98.4% | 16.7% | 10.4% |
| Dec 2021 | $1.13B | +8.4% | 98.7% | 9.0% | 7.9% |
| Dec 2020 | $1.05B | +32.7% | 99.0% | 15.6% | 38.9% |
| Dec 2019 | $788.10M | +74.7% | 99.1% | 9.2% | 4.7% |
| Dec 2018 | $451.20M | +179.2% | 98.9% | 8.2% | 4.7% |
| Dec 2017 | $161.63M | +977.5% | 99.2% | -81.3% | -88.2% |
| Dec 2016 | $15.00M | N/A | 100.0% | -982.5% | -940.6% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 40.2% from the year before. In the quarter ended Sep 2026, net income fell 1.4% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788.10M | $451.20M | $161.63M | $15.00M |
| Cost of revenue | $52.10M | $34.00M | $39.70M | $23.20M | $14.30M | $10.10M | $7.40M | $4.90M | $1.25M | $0 |
| Gross profit | $2.81B | $2.32B | $1.85B | $1.47B | $1.12B | $1.04B | $780.70M | $446.30M | $160.37M | $15.00M |
| Research and development | $1.03B | $743.60M | $708.90M | $463.80M | $433.40M | $439.50M | $354.30M | $160.60M | $121.83M | $94.29M |
| Operating income | $619.10M | $570.50M | $250.90M | $249.00M | $102.50M | $163.00M | $72.30M | $36.80M | -$131.36M | -$147.37M |
| Net income | $478.60M | $341.30M | $249.70M | $154.50M | $89.60M | $407.30M | $37.00M | $21.10M | -$142.54M | -$141.09M |
| EBITDA | $632.50M | N/A | $282.30M | $299.10M | $159.00M | $175.30M | $87.00M | $59.70M | -$115.42M | -$142.40M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.12B | $959.00M | $814.50M | $805.50M | $794.90M | $687.50M | $572.60M | $627.70M | $622.10M | $590.20M | $515.30M | $515.20M |
| Gross profit | $1.12B | $959.00M | $800.70M | $787.90M | $794.90M | $677.20M | $563.40M | $618.40M | $614.10M | $581.00M | $507.80M | $506.70M |
| Operating income | $331.30M | $151.50M | $193.40M | $210.90M | $239.00M | $145.60M | $23.60M | $142.00M | $183.80M | $145.40M | $99.30M | $150.30M |
| Net income | $206.50M | $144.40M | $197.90M | $153.70M | $209.50M | $107.50M | $7.90M | $103.10M | $129.80M | $65.00M | $43.40M | $147.70M |
Balance Sheet
As of Dec 2025, cash and equivalents of $713.00M were 15.4% of total assets of $4.63B, against total liabilities of $1.38B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993.15M | $817.59M | $365.09M |
| Current assets | $2.52B | $1.72B | $1.61B | $1.45B | $972.80M | $1.02B | $831.00M | $737.78M | $554.92M | $310.44M |
| Cash and equivalents | $713.00M | $233.00M | $251.10M | $262.90M | $340.80M | $187.10M | $112.30M | $141.71M | $254.71M | $83.27M |
| Total liabilities | $1.38B | $1.13B | $1.02B | $660.90M | $698.50M | $608.50M | $669.10M | $512.39M | $445.45M | $50.21M |
| Short-term debt | N/A | N/A | $170.10M | $169.40M | $0 | $10.30M | $408.80M | $62.34M | $38.37M | $14.86M |
| Long-term debt | N/A | N/A | N/A | N/A | $335.10M | $317.90M | $0 | $388.50M | $369.62M | $0 |
| Shareholder equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B | $636.90M | $480.76M | $372.14M | $314.88M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $5.63B | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | $3.25B |
| Total liabilities | $1.75B | $1.67B | $1.50B | $1.38B | $1.26B | $1.20B | $1.15B | $1.13B | $816.10M | $795.80M | $1.09B | $1.02B |
| Cash and equivalents | $641.50M | $332.40M | $266.50M | $713.00M | $340.20M | $264.00M | $194.10M | $233.00M | $349.10M | $139.70M | $396.30M | $251.10M |
| Shareholder equity | $3.88B | $3.69B | $3.41B | $3.25B | $3.00B | $2.69B | $2.54B | $2.59B | $2.72B | $2.51B | $2.39B | $2.23B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 95.7% of operating cash flow. Share repurchases came to 22.4% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $782.70M | $595.40M | $389.90M | $339.40M | $256.50M | $228.50M | $147.00M | $101.40M | -$94.33M | -$106.18M |
| Capital expenditures | $34.00M | $38.20M | $28.30M | $16.50M | $23.40M | $10.90M | $14.70M | $24.80M | $6.94M | $4.11M |
| Free cash flow | $748.70M | $557.20M | $361.60M | $322.90M | $233.10M | $217.60M | $132.30M | $76.60M | -$101.27M | -$110.29M |
| Share repurchases | $167.70M | $300.00M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$264.40M | -$126.80M | -$467.10M | -$177.10M | -$130.20M | $4.10M | -$211.10M | -$242.90M | -$251.25M | $112.95M |
| Financing cash flow | -$38.30M | -$486.70M | $65.30M | -$234.30M | $27.40M | -$157.80M | $32.40M | $29.50M | $516.65M | $2.39M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $395.20M | $136.40M | $145.80M | $388.40M | $227.50M | $102.00M | $64.80M | $242.50M | $158.00M | $64.60M | $130.30M | $123.50M |
| Capital expenditures | $11.60M | $7.80M | $9.10M | $2.40M | $13.20M | $12.50M | $10.70M | $7.30M | $8.10M | $11.60M | $11.20M | $5.40M |
| Free cash flow | $383.60M | $128.60M | $136.70M | $386.00M | $214.30M | $89.50M | $54.10M | $235.20M | $149.90M | $53.00M | $119.10M | $118.10M |
Frequently Asked Questions About NBIX
What is Neurocrine Biosciences' annual revenue?
Neurocrine Biosciences reported revenue of $2.86B for the fiscal year ended Dec 31, 2025.
How fast is Neurocrine Biosciences' revenue growing?
Revenue was up 21.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 24.3%.
Is Neurocrine Biosciences profitable?
Yes. Neurocrine Biosciences reported net income of $478.60M for the fiscal year ended Dec 31, 2025, with a net margin of 16.7%.
How much free cash flow does NBIX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $782.70M minus capital expenditures of $34.00M produced free cash flow of $748.70M.
How much debt does Neurocrine Biosciences have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $713.00M.
NBIX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors